2023-06-06 09:11:46
Two major studies were presented at ATS 2023 linking continuous positive airway pressure (CPAP) therapy to reduced all-cause mortality in patients with obstructive sleep apnea (OSAS).
The first study, led by Professor Jean-Louis Pépin, analyzed data from 100,000 French patients who had interrupted and then resumed their CPAP treatment. The results revealed a 38% lower risk of death from any cause in patients who maintained adherence to CPAP after re-starting treatment.
The second study, led by German researcher Holger Woehrle, involved more than 22,000 German patients. It concluded that treatment of OSAS with CPAP is associated with a 13% decrease in mortality during the first four years of treatment.
These two studies are a continuation of ResMed’s ALASKA study published in 2022, which revealed that patients who adhere to their CPAP treatment have a 39% greater chance of survival than those who interrupt it during the first year. .
ASV: a promising solution for central sleep apnea
The third study, led by German researcher Michael Arzt, was performed using data from READ-ASV, the largest prospective registry dedicated to studying the clinical use and effects of auto-assisted ventilation (ASV ). This study concluded that patients with central sleep apnea who used ASV treatment for the first time experienced a significant and clinically relevant improvement in their quality of life, particularly in relation to daytime sleepiness and sleep quality. .
“These studies, conducted by world-renowned researchers, highlight not only the effectiveness of CPAP and specifically ASV therapy for patients who need it, but also that better sleep and improved respiratory rate are intimately linked to our overall health,” said Carlos M. Nunez, Chief Medical Officer at ResMed.
Sleep apnea: a public health issue
It is estimated that 936 million people worldwide suffer from obstructive sleep apnea. This syndrome is characterized by abnormally frequent interruptions or reductions in breathing during sleep. These pauses can be repeated tens or even hundreds of times per night. Additionally, 5-10% of people with sleep-disordered breathing have central sleep apnea, where the brain stops sending signals to the body’s breathing muscles during sleep. Unfortunately, 80% of people with sleep apnea are often unaware of these wakeful episodes and go undiagnosed.
ResMed: at the forefront of technology for the treatment of sleep apnea
ResMed, a leading company in the field of innovative solutions for home treatment, is behind these groundbreaking studies. Their cloud-connected medical devices are transforming the care of patients with sleep apnea, COPD and other chronic conditions. By enabling better care in more than 140 countries, ResMed improves the quality of life of patients, reduces the impact of chronic diseases and lowers the costs of healthcare systems.
These new studies presented at ATS 2023 highlight the importance of continued research in the field of sleep apnea treatment. They also demonstrate the effectiveness of CPAP and ASV treatments, offering new insights for the millions of people suffering from this condition.
1686043915
#benefits #PPC #ASV #highlighted #ATS